Medical Advocates
HIV Infection/Disease
 
Facial Lipoatrophy Treatment
 
 
General Reports
Surgery
 Injection Therapy
Ultrasound
Growth Hormone




 

 
HIV Facial Lipoatrophy   Main New/Newsworthy Home Page  
Last Update:
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

General Reports
       

          Journal Papers, Abstracts, and Commentaries

 

Quality of life outcomes associated with treatment of human immunodeficiency virus (HIV) facial lipoatrophy.
Kraus CN, Chapman LW, Korta DZ, Zachary CB.
Int J Dermatol. 2016 Dec;55(12):1311-1320.
Abstract

FULL-TEXT ARTICLE
Adolescents with HIV and facial lipoatrophy: response to facial stimulation.
Gabana-Silveira JC, Mangilli LD, Sassi FC, et al
Clinics (Sao Paulo). 2014 Aug;69(8):574-578.
 Paper

High prevalence and impact on the quality of life of facial lipoatrophy and other abnormalities in fat tissue distribution in HIV-infected patients treated with antiretroviral therapy.
Leclercq P, Goujard CM Dr, Duracinsky M, et al
AIDS Res Hum Retroviruses. 2012 Dec 26..
 Abstract

FULL TEXT ARTICLE
 The Effect of Strength and Endurance Training on Insulin Sensitivity and Fat Distribution in HIV-Infected Patients with Lipodystrophy.
Carey D, Liew S, Emery S
 AIDS Rev. 2008 Apr-Jun;10(2):116-24.
 Abstract
 
Restorative Interventions for HIV Facial Lipoatrophy.
 Carey D, Liew S, Emery S.
Abstract
 
HIV-associated Facial Lipoatrophy - Review of Current Therapy Options.
Bechara FG, Sand M, Potthoff A, et al 
Eur J Med Res. 2008 Mar 31;13(3):93-9.
 Abstract
 
Long-term psychometric outcomes of facial lipoatrophy therapy: forty-eight-week observational,nonrandomized study.
 Orlando G, Guaraldi G, De Fazio D, et al
AIDS Patient Care STDS. 2007 Nov;21(11):833-42.
 Abstract  
 
Approaches to Treatment of HIV Facial Lipoatrophy.
Jones D
Skin Therapy Lett. 2005 Nov;10(9):5-7.
 Abstract
 
Management options for facial lipoatrophy.
Cofrancesco J Jr, Brown T, Martins CR.
AIDS Read. 2004 Dec;14(12):639-40, 645-50.
Abstract
 

         Conference Reports, Abstracts, and Posters
 
  Psychological assessment of HIV-infected patients with facial lipoatrophy before and after reparatory treatment
CR Fumaz, JA Muñoz-Moreno, M J Ferrer, et al
(15IAC)
 Abstract

Surgery
       
         News
 
  FDA Approves Radiesse for HIV-Associated Facial Lipidatrophy
 US FDA
December 23, 2006
 News Release

         Journal Papers, Abstracts, and Commentaries

 
Morcellized Omental Transfer for Severe HIV Facial Wasting.
Teplica D, Bohorquez M, Podbielski FJ.
Plast Reconstr Surg Glob Open. 2013 Dec 6;1(8):e73
 Abstract

Facelift in a Patient With Benign Symmetric Lipomatosis and HIV Facial Lipoatrophy: A Case Report.
Pinnella Z, Pinnella J.
Ann Plast Surg. 2013 Sep 18.
Abstract

Immediate versus Delayed Surgical Intervention for Reconstructive Therapy of HIV-Associated Facial Lipoatrophy: A Randomized Open-Label Study.
Narciso P, Bucciardini R, Tozzi V,  et al
 AIDS Res Hum Retroviruses. 2009 Oct 1
 Abstract

Adipose tissue hypertrophy after Lipostructure  in HIV patient with antiretroviral treatment. Case report and literature review.
Rousvoal A, Délia G, Casoli V, Martin D.
 Ann Chir Plast Esthet. 2009 Feb 13.
 Abstract
 
Correction of facial lipoatrophy using autologous fat transplants in HIV-infected adolescents.
Dollfus C, Blanche S, Trocme N, et al
HIV Med. 2009 Jan 28
 Abstract
 
Objective evidence for the use of polylactic acid implants in HIV-associated facial lipoatrophy using three-dimensional surface laser scanning and psychological assessment.
Ong J, Clarke A, White P, et al;
 J Plast Reconstr Aesthet Surg. 2008 Nov 24
 Abstract
 
Poly-L-lactic-acid filling of facial lipoatrophy in HIV+ patients under tritherapy,
Thiéry G, Coulet O, Adam S, Guyot L  .
 Rev Stomatol Chir Maxillofac. 2008 Mar 27
Abstract
 
Treatment of human immunodeficiency virus-associated facial lipoatrophy with lipofilling and submalar silicone implants.
Mori A, Lo Russo G, Agostini T, et al 
J Plast Reconstr Aesthet Surg. 2006;59(11):1209-16.
Abstract
 
Facial atrophy in HIV-related fat redistribution syndrome: a plastic surgical perspective on treatment options and a look to the future.
Abood A, Ong J, Withey S, et al
Int J STD AIDS. 2006 Apr;17(4):217-20.
Abstract
 
Lasting treatment of facial HIV and non HIV lipoatrophies through the use of SAM Gore Texmalar implants and polyacrylamide hydrogel filler Eutrophill About 90 consecutive cases.
 Mole B
 Ann Chir Plast Esthet. 2006 Mar 6;
 Abstract
 
Facial lipohypertrophy in HIV-infected subjects who underwent autologous fat tissue transplantation.
Guaraldi G, De Fazio D, Orlando G,et al
 Clin Infect Dis. 2005 Jan 15;40(2):e13-5.
 Abstract
 
The use of custom-designed midfacial and submalar implants in the treatment of facial wasting syndrome.
 Binder WJ, Bloom DC. et al
 Arch Facial Plast Surg. 2004 Nov-Dec;6(6):394-7
 Abstract

Treatment of human immunodeficiency virus-associated lipodystrophy with dermafat graft transfer to the malar area.
Strauch B, Baum T, Robbins N.
Plast Reconstr Surg. 2004 Jan;113(1):363-70; discussion 371-
 Abstract
 
Facial Atrophy in HIV-Related Fat Redistribution Syndrome: Anatomic Evaluation and Surgical Reconstruction.
 Talmor M, Hoffman LA, LaTrenta GS. Entrez PubMed
 Ann Plast Surg 2002 Jul;49(1):11-7
 Abstract

Ultrasound
       
              Journal Papers, Abstracts, and Commentaries
 
  Facial lipoatrophy and the place of ultrasound.
Ascher B, Katz P
 Dermatol Surg. 2006 May;32(5):698-708.
 Abstract

Growth Hormone
       
              Journal Papers, Abstracts, and Commentaries
 
  FULL TEXT PDF ARTICLE
 Effectiveness of Subcutaneous Growth Hormone in HIV-1 Patients with Moderate to Severe
Facial Lipoatrophy.
Honda M, Yogi A, Ishizuka N, et al
Intern Med. 2007;46(7):359-62.
 Paper

HIV Lipoatrophy Main Page   Main New/Newsworthy Home Page  

Facial Lipoatrophy Treatment